Evidence map›Paper›PMID 40988941›Full record

ArticleThe Chemist2025

Supernatural Products.

Dale L Boger

Abstract read
In one paragraph

Article in The Chemist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Dale L BogerDepartment of Chemistry, The Scripps Research Institute La Jolla, California 92037, USA.

Funding

ANTITUMORE ANTIBIOTICS: STREPTONIGRIN AND LAVENDAMYCINR01CA042056 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BOGER, DALE L · 1985 to 2024
$10.6M
LUZOPEPTINS, VANCOMYCIN AND RELATED AGENTSR01CA041101 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BOGER, DALE L · 1985 to 2024
$9.5M
Modulating Signaling Endocannabinoids and Fatty Acid AmidesR37DA015648 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI DALE L BOGER · 2018 to 2026
$3.8M
Modulating Signaling Endocannabinoids and Fatty Acid AmidesR01DA015648 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI BOGER, DALE L · 2002 to 2017
$3.7M
NCI NIH HHS R01 CA041101NCI NIH HHS R01 CA042056NIDA NIH HHS R01 DA015648NIDA NIH HHS R37 DA015648
6 · The paper itself

Abstract

The total synthesis of a series of natural products targeted by virtue of their biological properties are highlighted. Their complex structures inspired the development of new divergent synthetic strategies and synthetic methodology designed especially for the natural products of interest. The subsequent extension to the divergent total syntheses of key analogues that bear deep-seated structural changes are summarized that were used to define the structure-function properties of the natural products, to identify their biological target if unknown, to define fundamental features of their interaction with their biological target, and ultimately to improve their properties, producing supernatural products endowed with features not found expressed by the natural products themselves.

Indexed as

divergent synthesismedicinal chemistrynatural productssupernatural productstotal synthesis

Identifiers

PMID40988941
PMCPMC12452762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.